Rituximab in Hodgkin lymphoma: is the target always a hit? - PubMed (original) (raw)

Review

Rituximab in Hodgkin lymphoma: is the target always a hit?

Kamal S Saini et al. Cancer Treat Rev. 2011 Aug.

Abstract

In 1997, the anti-CD20 monoclonal antibody (MAb) rituximab became the first MAb approved for clinical use in oncology, and ushered in a new era of rationally designed targeted agents in cancer therapeutics. It is currently approved for use in non-Hodgkin lymphoma (NHL), chronic lymphoid leukemia (CLL), and rheumatoid arthritis (RA). Rituximab is non-mutagenic, associated with low treatment-related toxicity, and few, if any, long term adverse events, making it an attractive agent to be tried in off-label settings like Hodgkin lymphoma (HL). HL consists of two distinct subtypes - classic HL (cHL) and lymphocyte predominant HL (LPHL). CD20 is present in virtually all patients with LPHL, and in a significant minority of patients with cHL. In this CD20 positive sub-population, the use of rituximab is a rational intervention strategy. Rituximab has been used in patients with cHL as well as LPHL with good efficacy. In this article, we provide a clinically-oriented overview of the use of rituximab in the different sub-types of HL, and report updated results of our series of 8 LPHL patients treated with rituximab. A systematic review of the literature is also presented.

PubMed Disclaimer

Cited by

Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphoma.
Rael E, Rakszawski K, Koller K, Bayerl M, Butte M, Zheng H. Rael E, et al. Biomark Res. 2016 Mar 9;4:7. doi: 10.1186/s40364-016-0061-8. eCollection 2016. Biomark Res. 2016. PMID: 26966541 Free PMC article.
A Challenging Case of Primary Breast Hodgkin's Lymphoma.
Zarnescu NO, Iliesiu A, Procop A, Tampa M, Matei C, Sajin M, Costache M, Dumitru A, Lazaroiu AM. Zarnescu NO, et al. Maedica (Bucur). 2015 Mar;10(1):44-7. Maedica (Bucur). 2015. PMID: 26225149 Free PMC article.
Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group.
Appel BE, Chen L, Buxton A, Wolden SL, Hodgson DC, Nachman JB. Appel BE, et al. Pediatr Blood Cancer. 2012 Dec 15;59(7):1284-9. doi: 10.1002/pbc.24258. Epub 2012 Jul 27. Pediatr Blood Cancer. 2012. PMID: 22847767 Free PMC article. Clinical Trial.
The Evolution of Molecular Recognition: From Antibodies to Molecularly Imprinted Polymers (MIPs) as Artificial Counterpart.
Parisi OI, Francomano F, Dattilo M, Patitucci F, Prete S, Amone F, Puoci F. Parisi OI, et al. J Funct Biomater. 2022 Jan 28;13(1):12. doi: 10.3390/jfb13010012. J Funct Biomater. 2022. PMID: 35225975 Free PMC article. Review.
Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience.
Abuelgasim KA, Shammari RA, Alshieban S, Alahmari B, Alzahrani M, Alhejazi A, Alaskar A, Damlaj M. Abuelgasim KA, et al. Leuk Res Rep. 2021 Apr 8;15:100240. doi: 10.1016/j.lrr.2021.100240. eCollection 2021. Leuk Res Rep. 2021. PMID: 33936943 Free PMC article.

Rituximab in Hodgkin lymphoma: is the target always a hit? - PubMed (original) (raw)